Solitary sclerosis: Progressive myelopathy from solitary demyelinating lesion

Neurology

Volumn 78, Issue 8, 2012, Pages 540-544

  Schmalstieg, William F ^a   Keegan, B Mark ^a   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; ARTICLE; AUTOPSY; BRAIN STEM INJURY; CERVICAL SPINAL CORD INJURY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EVOKED BRAIN STEM AUDITORY RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEMIPARESIS; HUMAN; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUADRIPLEGIA; SEROLOGY; SPINAL CORD DISEASE;

EID: 84858122827     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318247cc8c     Document Type: Article

References (8)

1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the Mc- Donald criteria. Ann Neurol 2011;69:292-302.
2. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129:584-594. (Pubitemid 43278221)
3. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603-605.
4. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006;129:1507-1516. (Pubitemid 43999383)
5. Weinshenker BG, Gilbert JJ, Ebers GC. Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis. J Neurol Neurosurg Psychiatry 1990; 53:146-149. (Pubitemid 20067663)
6. Randomized controlled trial of interferon-β-1a in secondary progressive MS: clinical results. Neurology 2001;56: 1496-1504.
7. Panitch H, Miller A, Paty D, Weinshenker B. Interferon β-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795. (Pubitemid 39532370)
8. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebocontrolled trial. Ann Neurol 2007;61:14-24. (Pubitemid 46214240)